New drug cenobamate tested in real life for stubborn seizures
NCT ID NCT06716801
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study is tracking 300 adults with focal epilepsy whose seizures are not well controlled despite trying 2-3 other medications. Researchers are observing how well cenobamate works when added to their current treatment in real-world clinics across France, Germany, and Spain. The main goal is to see how many patients have at least a 50% reduction in seizures after 6 and 12 months of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cenobamate (a drug to reduce seizures)
What this could lead to
If successful, this study could show that cenobamate helps more people with hard-to-control focal seizures achieve better seizure control in everyday clinical practice.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also relatively small (300 participants) and early in real-world use, so findings may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOCAL EPILEPSY WITH AND WITHOUT SECONDARY GENERALIZATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital TARNIER COCHIN
RECRUITINGParis, France, France
Contact